LifeVantage (LFVN): Activating the Next Phase of Growth Through Science and Synergy

Send us Fan MailIn this episode of the WTR Small-Cap Spotlight podcast, Steve Fife, President & CEO, and Carl Aure, CFO of LifeVantage (NASDAQ: LFVN), join Tim Gerdeman and Doug Lane of Water Tower Research to discuss the company’s acquisition of LoveBiome, a fast-growing leader in gut health and direct sales.They explore how the deal strengthens LifeVantage’s foundation in nutrigenomics, expands its presence in the rapidly growing $14B gut health market, and creates synergies across product lines like P84 and MindBody. Fife and Aure also discuss the integration of consultant networks, expected financial impact, and how LifeVantage is positioning for long-term, science-driven growth.